Method of treating liver disease and like indications with vasodilating agents
AssigneePharmacy and Therapeutic Advisory Consultancy Ltd.
InventorAllan Joseph McLean
Life of this patent
Estimating the term…
Abstract
Liver diseases, such as cirrhosis of the liver, toxic and medicamentary liver damage, a liver-parenchymic disorder or hepatitis, are treated by administering to a human or animal subject in need thereof a therapeutically active or prophylactically effective low dose amount of a vasodilating agent which selectively increases the supply of oxygenated blood to the liver by increasing hepatic arterial inflow. Suitable vasodilating agents include calcium blockers, such as a benzothiazepine derivative, nifedipine, felodipine or verapamil.
Claims13
A method for the treatment of liver disease selected from the group consisting of cirrhosis of the liver, toxic and medicamentary liver damage, a liver parenchymic disorder or hepatitis, which method comprises administering to a human or animal subject in need thereof a therapeutically active or prophylactically effective low dose amount of approximately 2.5 to 60 mg per day of a vasodilating agent which selectively increases the supply of oxygenated blood to the liver by increasing hepatic arterial inflow, wherein said vasodilating agent is selected from benzothiazepine compounds of the formula ##STR3## wherein R.sup.1 is a phenyl group substituted or not with 1 to 3 lower alkyl groups, lower alkoxy groups or halogen atoms, R.sup.2 is a hydrogen atom or a lower alkanoyl group, R.sup.3 and R.sup.4 are each a lower alkyl group and may be the same or different, X is a hydrogen atom or a halogen atom and Y is an alkylene group of 2 or 3 carbon atoms, or its non-toxic acid-addition salt.
An oral composition for the treatment of liver disease selected from the group consisting of cirrhosis of the liver, toxic and medicamentary liver damage, a liver parenchymic disorder or hepatitis, which composition comprises approximately 2.5 to 60 mg per day of a vasodilating agent, said composition being effective to selectively increase the supply of oxygenated blood flow to the liver by increasing hepatic arterial inflow, wherein said vasodilating agent is selected from benzothiazepine compounds of the formula ##STR4## wherein R.sup.1 is a phenyl group substituted or not with 1 to 3 lower alkyl groups, lower alkoxy groups or halogen atoms, R.sup.2 is a hydrogen atom or a lower alkanoyl group, R.sup.3 and R.sup.4 are each a lower alkyl group and may be the same or different, X is a hydrogen atom or a halogen atom and Y is an alkylene group of 2 or 3 carbon atoms, or its non-toxic acid-addition salt, and in a pharmaceutically safe diluent or carrier therefor.
Dependencies are inferred from the claim text.